Glancy Prongay & Murray LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit against Esperion The...
March 08 2016 - 10:30AM
Business Wire
Glancy Prongay & Murray LLP (“GPM”) reminds investors that a
class action complaint has been filed on behalf of a class of
investors who purchased Esperion Therapeutics, Inc. (“Esperion” or
the “Company”) (Nasdaq: ESPR) securities between August 18, 2015
and September 28, 2015, inclusive (the “Class Period”).
Esperion investors have until March 14, 2016 to file a lead
plaintiff motion. Investors are encouraged to contact GPM to
discuss their legal rights.
The complaint alleges that throughout the Class Period,
Defendants made materially false and misleading statements
regarding Esperion's business and prospects to shareholders,
including that there was no clear path to approval for ETC-1002,
that the FDA had encouraged Esperion to initiate a cardiovascular
outcomes trial ("CVOT") and that completion of a CVOT could be
necessary prior to approval of ETC-1002. Upon disclosure that the
Company would need to perform additional CVOTs prior to approval,
shares of Esperion fell dramatically, over $16 per share, or nearly
50%, to close on September 29, 2015 at $18.33 per share.
If you purchased shares of Esperion during the Class Period you
may move the Court no later than March 14, 2016 to request
appointment as lead plaintiff. If you have information or would
like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire,
of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California
90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to
shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160308005440/en/
Glancy Prongay & Murray LLP, Los AngelesLesley Portnoy,
310-201-9150 or
888-773-9224shareholders@glancylaw.comwww.glancylaw.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024